ArticleAmerican journal of translational research2025
Urinary exosomal miR-320b as a biomarker of tubular atrophy/interstitial fibrosis in IgA nephropathy patients.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTubular atrophy/interstitial fibrosis (TA/IF) is an independent risk factor for the progression of immunoglobulin A nephropathy (IgAN), with its assessment primarily relying on renal biopsy. Therefore, this study aimed to identify novel non-invasive biomarkers for the dynamic evaluation of TA/IF in IgAN patients.
methodsIgAN patients were divided into T0 (TA/IF ≤ 25%) and T1 (TA/IF > 25%) groups. Urine exosomes were isolated from morning samples by ultracentrifugation and characterized using electron microscopy, nanoparticle tracking, and western blot. High-throughput sequencing, real-time quantitative polymerase chain reaction (RT-qPCR), and receiver operating characteristic curve (ROC) analysis identified microRNA-320b (miR-320b) as the best candidate for predicting TA/IF scores in IgAN. Hence, the association between miR-320b expression and clinical data was evaluated.
resultsCompared to the T0 group, significantly higher blood urea nitrogen (BUN), serum creatinine (Scr), uric acid (UA), and 24-hour urine protein quantification (24UP) levels were observed in the T1 group. In contrast, hemoglobin (Hb), albumin (Alb), and estimated glomerular filtration rate (eGFR) were lower (P < 0.05). In the T1 group, 9 miRNAs were upregulated and 16 were downregulated. RT-qPCR analysis revealed that these 9 miRNAs were significantly overexpressed in the T1 group (P < 0.05), with miR-320b showing the most significant upregulation (P < 0.001). In addition, ROC curve analysis indicated that miR-320b had good diagnostic efficacy (AUC = 0.8785, P = 0.0017). Spearman correlation analysis revealed that miR-320b expression was positively linked to 24UP, BUN, Scr, and UA, and negatively linked to eGFR.
conclusionUrine exosomal miR-320b is a non-invasive biomarker that can effectively predict TA/IF scores in IgAN patients, offering a promising alternative for diagnosing renal fibrosis in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.